CA2179314A1 - Esters and amides of 9(z)-retinoic acid - Google Patents
Esters and amides of 9(z)-retinoic acidInfo
- Publication number
- CA2179314A1 CA2179314A1 CA002179314A CA2179314A CA2179314A1 CA 2179314 A1 CA2179314 A1 CA 2179314A1 CA 002179314 A CA002179314 A CA 002179314A CA 2179314 A CA2179314 A CA 2179314A CA 2179314 A1 CA2179314 A1 CA 2179314A1
- Authority
- CA
- Canada
- Prior art keywords
- retinoic acid
- amides
- esters
- alkyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 150000001408 amides Chemical class 0.000 title claims abstract description 13
- 150000002148 esters Chemical class 0.000 title claims abstract description 12
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 150000003254 radicals Chemical class 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000006994 Precancerous Conditions Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- -1 -NHz Chemical group 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 description 1
- NHBJPPQEPIPTLF-UHFFFAOYSA-N 2-chloro-1-(3,4-dimethoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CCl)C=C1OC NHBJPPQEPIPTLF-UHFFFAOYSA-N 0.000 description 1
- XGRNMEBMWPBPRT-UHFFFAOYSA-N 2-chloro-1-(3-fluorophenyl)ethanone Chemical compound FC1=CC=CC(C(=O)CCl)=C1 XGRNMEBMWPBPRT-UHFFFAOYSA-N 0.000 description 1
- UJZWJOQRSMOFMA-UHFFFAOYSA-N 2-chloro-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C=C1 UJZWJOQRSMOFMA-UHFFFAOYSA-N 0.000 description 1
- MCRINSAETDOKDE-UHFFFAOYSA-N 2-chloro-1-(4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CCl)C=C1 MCRINSAETDOKDE-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Esters and amides of 9 (Z) -retinoic acid for the treatment of carcinomas, novel 9 (Z) -retinoic acid derivatives, pharmaceutical compositions containing esters and amides of 9 (Z) -retinoic acid as anticancer agents, and the use of esters and amides of 9 (Z)-retinoic acid for the treatment and prophylaxis of carcinomas.
Description
~ ~ 21~93~4 Esters and amides of 9 ( Z )-retlnoic acid The invention rRlates to esters and amides of 9 ( Z )-retinoic acid for the treatment of carcinomas, to novel 9(Z)-retinoic acid derivatives and to ph~rr~ utical compositions containing esters and amides of 9(Z)-retinoic acid, and to the use thereof for the treatment of carcinomas.
10 ~etinoic acids (vitamin A acids) are derivatives of vitamin A
( retinol ) covering a wide range of biological activities, such as cellular differentiation and many others. Their biological activ-lty is made possible by interaction with two families of nuclear receptors (RA receptor and ~X receptor) (cf. Mol. Cell. Biol. 14 No. 4 (1994) 2323 - 30).
The use of all-(E)- or 13-(Z)-retinoic acids or their derivatives in the therapy of acne has been known for a long time (cf.
US 3,729,568 and E~ 366 713). Use of 9(Z)-retinoic acid in the 20 treatment of cancer has been considered only since the identifi-cation of specific receptor systems [cf. Cell 68 (1992) 397 -406; Nature ~L (1993) 657 - 60; Nucl. Acid Research 21, No. 5 (1993) 1231 - 37; ~ifferentiation 54 (lg93) 123 - 29; J. Bio.
Chem. 26~ (1994) 16689 - 95, Blood ~2, No. 12 (1993) 35g2 - 99;
Blood ~, No. 10 (19g3) 22].
already known for the structural isomers all-E- and 13(Z)-retinoic acid, in some cases severe side effects occur on use of 9(Z)-retinoic acid too, 80 that the extent of secondary reactions 30 disproportionately overcompensates for the effect achieved. In addition, topical use of free g(Z)-ret$noic acid frequently leads to severe derm~l irrltation and pain for the patient which depends on the concentration and f requency of application . The type and number of side effects reduce the possibility of therapy with high doses of free 9 ( Z )-retlnoic acid and re3tri~ t the number of areas of application.
We have now found that certain esters and amides of 9 ( Z ) -retinoic acid can also be used for treating carcinomas but, at the same gO time, show only few, if any, side effects. The present invention therefore relates to derivatives of 9(2)-retinoic acid which can easily be prepared and are of importance for the treafment of carcinomas while simultaneously minim~7;ng the toxicological side effects of free 9(Z)-vitamin A acid.
~ 2 2~7~3~
The invention therefore relates to compounds for use for treating carcinomas, of the general formula I
X~
C~
~y (I), where Y can be the following radicals:
--O--CRI--CO--R2, where Rl i5 H or Cl-C20-alkyl or Cl-C20-alkanoyl, preferably H or 20 Cl-C4-alkyl, and R2 i8 Cl-C4-alkyl, -CH20H, 2 -CH2-o-co-R3 n ' Xn, Xn ~ Xn ~
and where R3 is H or Cl-C4-alkyl, X is H, F, Cl, E~r, I, -OH, -oR3, -NH2, -N02, -CN, -NHR3, -NR3 30 -sH, sR3, -o-co-R3, -Co-R3, -CHO or -CO-ORI, 2 and n is an integer from O to S, or else Y i8 ~ 217~314 --O--CH2~ CH3 --O--CHz~ oCH3~
--O--CH2~ F; --~--CH2--CO-- NH~--CH3 -- N~ ~ COOH ; --NH ~ ;
COOH
--O~CE~2--CO ~ OCH3 OCE;3 `J~J~l ;
~
~o.~
-- O--CHR4 O--CHR3--O--CO--oR3 ~ CHz--O--CO--R
--O--CRI--CH
O -- --CO --Rl --N~ ; _ NR3 ~ ; --NR4 ~ xn r o 4 17~
where Rl, R3, X and n have the abovementioned meanings, and R4 is -Co-oR3, -Co-R3 or -Co-R3 ~~ Xn ~
where in the compounds which contain several R~, R2, R3 and/or R4 radicals, these can be ldentical or different, or Qlse Y i8 one of the radicals ORs ORs Rs 1 Z~
ORs ORs R300C ~ O- R300C /. ~ ,~NR3--RsO ~ /, OR Rs \ ~ I~ ' ~ ORs oR5 ORs where R3 has the abovementioned meaning, and Rs is H or Cl--C4-alkyl or C~--C4-alkanoyl.
Of particular importance for use for treating carcinomas are com-30 pounds of the general formula I where Y is the radical --O--CRI--CO--~
Xn where Rl is H, X is F, -OH, -OCH3, -NHz, -CN, -NHCH3 or -N(CH3) 2, and n is an integer from 1 to 5, preferably 1 to 3, in parti~ular 40 1 to 2, and the compounds of the general ~ormula I
where Y is one of the radicals 21793I~
RsO~ ~ NR -- RsO :~ 7~ z NR
ORs ORs WherQ Rs i8 H or Cl-C4-alkanoyl such as CH3_CO-, C2Hs-CO-, C3H7-CO
10 or else HCO- and R3 18 H, Cl-C4-alkyl or Cl-C4-alkanoyl, in particular compounds of the general formula I where Y is one of the radicals J ,~,~ ;
~J:~ ~
.~
O
-NH--~ ~ CO-OCH3 or CH3CO-O ~~~ O-COCH3 -NH--~ ~ CH2OH
CH3COO ~ ~-COCH3 The 9 ( Z ) -retinoic acid derivatives according to the invention can bQ used both locally, le. topically, for treating cancer of the Rkin and orally, le. systemioally, for treating carcinomas or precancerous states.
E~owever, under cQrtain conditions, local and systemic prophylaxis of carcinomas is also possible.
The invention therefore also relates to pharmaceutical compos1-10 tions containing compounds of the general formula I ln addltlon to conventlonal pharmaceutlcal exclplents or diluents and conventlonal pharmaceutical ancillary substances, and to the use of ~ ullds of the general formula I in the form of pastes, gels, ointments, oreams, lotlons, dustlng powders, solutions or emulsions containing from 0 . 001 to 5~ of these compounds for the local treatment of oarcinoman or precancerous states, and to the use of a compound of the general formula I in the form of tablQts, film-coated tablets, sugar-coated tablQts, capsulQs, pills, powders, 20 granules, solutions or suspensions for the ~ystemic treatment of carcinomas or precancerous states, and to the use of pharmaceuti-cal composltions containing compounds of the general formula }
for the local or systemic prophylaxis of carcinomas.
The therapeutic compositions or formulations containing conven-tional excipients or diluents and, wherQ appropriatQ, conven-tion~l rh~rr-^eutical ancillary substances appropriate for thQ
requirQd modQ of adm$nistration with a dosage suitable for use are produced in a conventional way, in partioular by mixing. ThQ
30 therapeutic compositions contain thQ . ~ul~ds to bo used accord-ing to the invention in amounts of from 0.001 to 5~ by wQight, prQferably from 0.001 to 1~ by weight, for local use, and preferably ln a slngle dose of from 0.1 to 10 mg ~or systemic use .
Tests relating to topical use are carried out by generally customary oncology tQsting programs.
The supprQssion of uncontrolled cell growth is tested.
The preparation of compounds according to the invention of the general formu a I is indicated by the following examples.
7 217931~
Example 1 2- [ 9 ( Z ) -Retinoyloxy ] -4 ' -methylacetophenone 50 ml of dimethylformamide were introduced into a flask and then 0.5 g of potassium carbonate and 1.12 g of 2-chloro-4'-mQthyl-acetophenone plus 2 g of 9 ( Z ) -retinoic acid were added with exclusion of light. The mixture was stirred under nitrogen at 10 room temperature (RT) for 24 hours (h). 100 ml of water were then ~dded to the reaction mixture, and stirring was continued for 2 h. The re~ulting crystals were filtered off with suction and dried under nitrogen at 30 C for 12 h. 2.4 g (~vLLe~vl~ding to a yiQld of 84& of theory) of the abovementioned product were obtained. The product was purified by recrystallization ~rom isopropanol. 'rhe melting point of the recrystallized product was 126 C. The NMR spectra agree with the proposed structure.
Example 2 2--[ 9 ( Z ) -Retinoyloxy l--4 ~ -methoxyace~nphc-~n~
A mixture of 35 ml of dimethylformamide, 0.5 g of potassium carbonate, 1. 23 g of 2-chloro-4 '-methoxyacetophenone and 2 g of 9 ( Z )-retinoic acid was stirred under N2 at RT with exclusion of light for 24 h. 100 ml of water were then added to the reaction mixture at 30 C, and stirring was continued for 2 h. The resulting crystals were filtered off with suction and dried under nitrogen for 12 h. 2.5 g (corresponding to 88.1~ of theory) of the above-30 mentioned product were obtained. The melting point afterrecrystallization from isopropanol was 124-126 C.
Example 3 2-[ 9 ( Z )-Retinoyloxy]-4 '-fluoroacetophenone A mixture of 30 ml of dimethylformamide, 0.2 g of pot~ssium carbonate, 0.54 g of 2-chloro-4'-fluoroacetophenone and 1 g of 9 ( Z ) -retinoic acid was atirred under N2 at RT with exclusion of 40 light for 24 h. 100 ml of water were then added, and stirring was continued ~or 2 h. Removal of the crystals and drying under nitrogen for 12 hours resulted in 1.1 g (84.69~ of theory) of the abovementioned product. The melting point after purification by recrystallization from methanol was 99 C.
ExamplQ 4 2--[9(Z)-Retinoyloxy]--3'--fluoroacetophenone A mixture of 50 ml of dimethylformamide, 0.75 g of potassium carbonate, 1. 8 g of 2-chloro-3 '-fluoroacetophenone and 3 g of 9 ( Z )-retinoic acid was stirred under nitrogen at RT with exclusion of light for 24 h. 100 ml of water were then added to the reaction mixture, and stirring was continued for 2 h. The 10 resulting crystals were filtered off with suction and recrystal-lized from isopropanol. 3.3 g (85% of theory) of the abovementioned product were obtained with a melting point of 76-79 C.
Example 5 2--[ 9 ( Z ) -Retinoyloxy ] -N- ( 2, 6-dimethylphenyl ) acetamide A mixture of 35 ml of dimethylformamide, 0 . 5 g of potassium 20 carbonate, 1.3 g of 2-chloro-N-(2,6-dimethylphenyl)acQtamide and 2 g of 9 ( Z )-retinoic acid was stirred under nitrogen at RT with exclu~ion of light for 24 h. 100 ml of water were then added to the reaction mixture, and the mixture was thQn stirred for 2 h.
The resulting crystals were dried under nitrogen for 12 h.
Recrystalli2ation from isopropanol resulted in 2.4 g (91% of theory) of the abovementioned product with a solidification point of 147-148 C.
Example 6 N- ( p-Carboxyphenyl ) -9 ( Z ) -retinoamide A mixture of 10 g of 9 ( Z )-retinoic acid and 2 . 9 g of pyridine in 650 ml of diethyl ether was cooled to 0 C. Then, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the mixture was stirred at 0 C for 2 h. Precipitated pyridinium hydrochloridQ was removed.
The filtrate waD then cooled to -25 C and a solution of 4.1 g of p-aminobenzoic acid in 150 ml of diethyl ether and 2.9 g of pyridine was added. The mixture was stirred at RT for 2 h. For 40 workup, the reaction mixture was qxtracted with ice-cold 1 N i~Cl and saturated NaCl solution. The aqueous phase was separated of f ~nd the solvent was removed under reduced pressure to result in 11.7 g (93r of theory) of the abovementioned product which, after recrystallization from isopropanol/ethanol, had a solidification point of 187 C.
9 3 I ~
Example 7 2- [ 9 ( Z ) -Retinoyloxy ]--3 ', 4 ' -dimethoxyacetophenone A mixture of 50 ml of dimethylformamide, 0.75 g of potassium carbonate, 2 . 2 g of 2-chloro-3 ', 4 ' -dimethoxyacetophenone and 3 g of 9 ( Z ) -retinoic acid was stirred under nitrogen at RT with excluslon of light for 24 h. For workup, 100 ml of water were added to the reaction mixture, which was then stirred at RT for 10 2 h. The precipitated crystals were filtered off with suction, recrystallized from isopropanol and dried under nitrogen. This resulted in 3.6 g (969~ of theory) of crystallized product of melting point 130-C.
Example 8 N- [ 1--( D-Glucopyranosyluronosyl ) ] -9 ( Z ) -retinoamide A mixture of 10 g of 9(Z)-retinoic acid and 2.9 g of pyridine in 20 500 ml of diethyl ether was cooled to 0 C under N2 with exclusion of light. Then, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the mixture was stirred at 0 C for 2 h. Precipitated pyridinium hydrochlorida was removed. The filtrate was then cooled to --25 C and a solution of 10 g of methyl (2,3,4-tri-o-acetyl-f~--D--glucopyranosyluronosyl)amine in 150 ml of diethyl ether and 4 . 2 g of potassium carbonate were added. The mixture was stirred at -25 C fo 2 h and warmed to 0 C over the course of 1 h. Then 2 g of potassium carbonate and 100 ml of methanol were added to the reaction mixture. To remove the protective groups, a 30 20~ strength solution of ROE~ in 150 ml of methanol was then added. The reaction mixture was heated at 60 C for 0.5 h and then cooled to RT. After extraction with heptane/ethyl acetatQ, the aqueous phases were extracted several times with methylene chloride. The methylene chloride phases were then concentrated under reduced pressure. The residue was fractionated into a 1:1 mixture of the two anomers by chromatography on silica gel. This 1:1 mixture of isomers of the abovementioned product was obtained in amounts of 8.2 g (corre~ponding to 609~ of theory) with a solidification point of 56-58 C.
Example 9 Tocopheryl 9 ( Z ) -retinoate 6 g of 9(Z)-retinoic acid were dissolved in 150 ml of diisopropyl ether, and the solution was cooled to 5 C. Then 4 . 6 g of tri-f luoroacetic anhydride were added dropwise, and the reaction lo 2~9~1d mixture waa warmed to RT . A solut1on of 9 . 6 g of D, L-tocopherol in 10 ml of diisopropyl ether was then added dropwise, and the mixture was stirred at RT for 1 h. For workup, 20 ml of agueous ammonia were added to the mixture at 20 - 25 C. After phase Eieparation, the organic phase was wa3hed with water, dried and then distllled to remove the solvent. 12 g (corresponding to 84 of theory) of the abovementioned product were obtained in the form of an orange-yellow oil whose NMR data agree with the proposed structure.
Example 1 0 Ergocalciferyl 9 ( Z )-retinoate A mixture of 10 g of 9(Z)-retinoic acid, 2.9 g of pyridine and 500 ml of diethyl ether was cooled under N2 protective gas with exclusion of light to 0 C and, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the reaction mixture was stirred at 0 C
for 2 h. Precipitated pyridinium hydrochloride wa~ removed. The 20 filtrate was cooled to -2S C and a solution o~ 13.2 g of ergo-calciferol in lS0 ml of diethyl ether and 4.2 g of potassium carbonate were added. The mixture was stirred at -25 C for 2 h and then warmed to 0 C over the course of 1 h. 'rhen lO~t strength aqueous KHC03 solution was added to the reaction mixture, followed by wash$ng with water. Removal of the solvent by distillation resulted in lS g of the abovementioned product in the form of a dark orange oil. The NMR spectra are consistent with the propo3ed ~ tructure .
10 ~etinoic acids (vitamin A acids) are derivatives of vitamin A
( retinol ) covering a wide range of biological activities, such as cellular differentiation and many others. Their biological activ-lty is made possible by interaction with two families of nuclear receptors (RA receptor and ~X receptor) (cf. Mol. Cell. Biol. 14 No. 4 (1994) 2323 - 30).
The use of all-(E)- or 13-(Z)-retinoic acids or their derivatives in the therapy of acne has been known for a long time (cf.
US 3,729,568 and E~ 366 713). Use of 9(Z)-retinoic acid in the 20 treatment of cancer has been considered only since the identifi-cation of specific receptor systems [cf. Cell 68 (1992) 397 -406; Nature ~L (1993) 657 - 60; Nucl. Acid Research 21, No. 5 (1993) 1231 - 37; ~ifferentiation 54 (lg93) 123 - 29; J. Bio.
Chem. 26~ (1994) 16689 - 95, Blood ~2, No. 12 (1993) 35g2 - 99;
Blood ~, No. 10 (19g3) 22].
already known for the structural isomers all-E- and 13(Z)-retinoic acid, in some cases severe side effects occur on use of 9(Z)-retinoic acid too, 80 that the extent of secondary reactions 30 disproportionately overcompensates for the effect achieved. In addition, topical use of free g(Z)-ret$noic acid frequently leads to severe derm~l irrltation and pain for the patient which depends on the concentration and f requency of application . The type and number of side effects reduce the possibility of therapy with high doses of free 9 ( Z )-retlnoic acid and re3tri~ t the number of areas of application.
We have now found that certain esters and amides of 9 ( Z ) -retinoic acid can also be used for treating carcinomas but, at the same gO time, show only few, if any, side effects. The present invention therefore relates to derivatives of 9(2)-retinoic acid which can easily be prepared and are of importance for the treafment of carcinomas while simultaneously minim~7;ng the toxicological side effects of free 9(Z)-vitamin A acid.
~ 2 2~7~3~
The invention therefore relates to compounds for use for treating carcinomas, of the general formula I
X~
C~
~y (I), where Y can be the following radicals:
--O--CRI--CO--R2, where Rl i5 H or Cl-C20-alkyl or Cl-C20-alkanoyl, preferably H or 20 Cl-C4-alkyl, and R2 i8 Cl-C4-alkyl, -CH20H, 2 -CH2-o-co-R3 n ' Xn, Xn ~ Xn ~
and where R3 is H or Cl-C4-alkyl, X is H, F, Cl, E~r, I, -OH, -oR3, -NH2, -N02, -CN, -NHR3, -NR3 30 -sH, sR3, -o-co-R3, -Co-R3, -CHO or -CO-ORI, 2 and n is an integer from O to S, or else Y i8 ~ 217~314 --O--CH2~ CH3 --O--CHz~ oCH3~
--O--CH2~ F; --~--CH2--CO-- NH~--CH3 -- N~ ~ COOH ; --NH ~ ;
COOH
--O~CE~2--CO ~ OCH3 OCE;3 `J~J~l ;
~
~o.~
-- O--CHR4 O--CHR3--O--CO--oR3 ~ CHz--O--CO--R
--O--CRI--CH
O -- --CO --Rl --N~ ; _ NR3 ~ ; --NR4 ~ xn r o 4 17~
where Rl, R3, X and n have the abovementioned meanings, and R4 is -Co-oR3, -Co-R3 or -Co-R3 ~~ Xn ~
where in the compounds which contain several R~, R2, R3 and/or R4 radicals, these can be ldentical or different, or Qlse Y i8 one of the radicals ORs ORs Rs 1 Z~
ORs ORs R300C ~ O- R300C /. ~ ,~NR3--RsO ~ /, OR Rs \ ~ I~ ' ~ ORs oR5 ORs where R3 has the abovementioned meaning, and Rs is H or Cl--C4-alkyl or C~--C4-alkanoyl.
Of particular importance for use for treating carcinomas are com-30 pounds of the general formula I where Y is the radical --O--CRI--CO--~
Xn where Rl is H, X is F, -OH, -OCH3, -NHz, -CN, -NHCH3 or -N(CH3) 2, and n is an integer from 1 to 5, preferably 1 to 3, in parti~ular 40 1 to 2, and the compounds of the general ~ormula I
where Y is one of the radicals 21793I~
RsO~ ~ NR -- RsO :~ 7~ z NR
ORs ORs WherQ Rs i8 H or Cl-C4-alkanoyl such as CH3_CO-, C2Hs-CO-, C3H7-CO
10 or else HCO- and R3 18 H, Cl-C4-alkyl or Cl-C4-alkanoyl, in particular compounds of the general formula I where Y is one of the radicals J ,~,~ ;
~J:~ ~
.~
O
-NH--~ ~ CO-OCH3 or CH3CO-O ~~~ O-COCH3 -NH--~ ~ CH2OH
CH3COO ~ ~-COCH3 The 9 ( Z ) -retinoic acid derivatives according to the invention can bQ used both locally, le. topically, for treating cancer of the Rkin and orally, le. systemioally, for treating carcinomas or precancerous states.
E~owever, under cQrtain conditions, local and systemic prophylaxis of carcinomas is also possible.
The invention therefore also relates to pharmaceutical compos1-10 tions containing compounds of the general formula I ln addltlon to conventlonal pharmaceutlcal exclplents or diluents and conventlonal pharmaceutical ancillary substances, and to the use of ~ ullds of the general formula I in the form of pastes, gels, ointments, oreams, lotlons, dustlng powders, solutions or emulsions containing from 0 . 001 to 5~ of these compounds for the local treatment of oarcinoman or precancerous states, and to the use of a compound of the general formula I in the form of tablQts, film-coated tablets, sugar-coated tablQts, capsulQs, pills, powders, 20 granules, solutions or suspensions for the ~ystemic treatment of carcinomas or precancerous states, and to the use of pharmaceuti-cal composltions containing compounds of the general formula }
for the local or systemic prophylaxis of carcinomas.
The therapeutic compositions or formulations containing conven-tional excipients or diluents and, wherQ appropriatQ, conven-tion~l rh~rr-^eutical ancillary substances appropriate for thQ
requirQd modQ of adm$nistration with a dosage suitable for use are produced in a conventional way, in partioular by mixing. ThQ
30 therapeutic compositions contain thQ . ~ul~ds to bo used accord-ing to the invention in amounts of from 0.001 to 5~ by wQight, prQferably from 0.001 to 1~ by weight, for local use, and preferably ln a slngle dose of from 0.1 to 10 mg ~or systemic use .
Tests relating to topical use are carried out by generally customary oncology tQsting programs.
The supprQssion of uncontrolled cell growth is tested.
The preparation of compounds according to the invention of the general formu a I is indicated by the following examples.
7 217931~
Example 1 2- [ 9 ( Z ) -Retinoyloxy ] -4 ' -methylacetophenone 50 ml of dimethylformamide were introduced into a flask and then 0.5 g of potassium carbonate and 1.12 g of 2-chloro-4'-mQthyl-acetophenone plus 2 g of 9 ( Z ) -retinoic acid were added with exclusion of light. The mixture was stirred under nitrogen at 10 room temperature (RT) for 24 hours (h). 100 ml of water were then ~dded to the reaction mixture, and stirring was continued for 2 h. The re~ulting crystals were filtered off with suction and dried under nitrogen at 30 C for 12 h. 2.4 g (~vLLe~vl~ding to a yiQld of 84& of theory) of the abovementioned product were obtained. The product was purified by recrystallization ~rom isopropanol. 'rhe melting point of the recrystallized product was 126 C. The NMR spectra agree with the proposed structure.
Example 2 2--[ 9 ( Z ) -Retinoyloxy l--4 ~ -methoxyace~nphc-~n~
A mixture of 35 ml of dimethylformamide, 0.5 g of potassium carbonate, 1. 23 g of 2-chloro-4 '-methoxyacetophenone and 2 g of 9 ( Z )-retinoic acid was stirred under N2 at RT with exclusion of light for 24 h. 100 ml of water were then added to the reaction mixture at 30 C, and stirring was continued for 2 h. The resulting crystals were filtered off with suction and dried under nitrogen for 12 h. 2.5 g (corresponding to 88.1~ of theory) of the above-30 mentioned product were obtained. The melting point afterrecrystallization from isopropanol was 124-126 C.
Example 3 2-[ 9 ( Z )-Retinoyloxy]-4 '-fluoroacetophenone A mixture of 30 ml of dimethylformamide, 0.2 g of pot~ssium carbonate, 0.54 g of 2-chloro-4'-fluoroacetophenone and 1 g of 9 ( Z ) -retinoic acid was atirred under N2 at RT with exclusion of 40 light for 24 h. 100 ml of water were then added, and stirring was continued ~or 2 h. Removal of the crystals and drying under nitrogen for 12 hours resulted in 1.1 g (84.69~ of theory) of the abovementioned product. The melting point after purification by recrystallization from methanol was 99 C.
ExamplQ 4 2--[9(Z)-Retinoyloxy]--3'--fluoroacetophenone A mixture of 50 ml of dimethylformamide, 0.75 g of potassium carbonate, 1. 8 g of 2-chloro-3 '-fluoroacetophenone and 3 g of 9 ( Z )-retinoic acid was stirred under nitrogen at RT with exclusion of light for 24 h. 100 ml of water were then added to the reaction mixture, and stirring was continued for 2 h. The 10 resulting crystals were filtered off with suction and recrystal-lized from isopropanol. 3.3 g (85% of theory) of the abovementioned product were obtained with a melting point of 76-79 C.
Example 5 2--[ 9 ( Z ) -Retinoyloxy ] -N- ( 2, 6-dimethylphenyl ) acetamide A mixture of 35 ml of dimethylformamide, 0 . 5 g of potassium 20 carbonate, 1.3 g of 2-chloro-N-(2,6-dimethylphenyl)acQtamide and 2 g of 9 ( Z )-retinoic acid was stirred under nitrogen at RT with exclu~ion of light for 24 h. 100 ml of water were then added to the reaction mixture, and the mixture was thQn stirred for 2 h.
The resulting crystals were dried under nitrogen for 12 h.
Recrystalli2ation from isopropanol resulted in 2.4 g (91% of theory) of the abovementioned product with a solidification point of 147-148 C.
Example 6 N- ( p-Carboxyphenyl ) -9 ( Z ) -retinoamide A mixture of 10 g of 9 ( Z )-retinoic acid and 2 . 9 g of pyridine in 650 ml of diethyl ether was cooled to 0 C. Then, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the mixture was stirred at 0 C for 2 h. Precipitated pyridinium hydrochloridQ was removed.
The filtrate waD then cooled to -25 C and a solution of 4.1 g of p-aminobenzoic acid in 150 ml of diethyl ether and 2.9 g of pyridine was added. The mixture was stirred at RT for 2 h. For 40 workup, the reaction mixture was qxtracted with ice-cold 1 N i~Cl and saturated NaCl solution. The aqueous phase was separated of f ~nd the solvent was removed under reduced pressure to result in 11.7 g (93r of theory) of the abovementioned product which, after recrystallization from isopropanol/ethanol, had a solidification point of 187 C.
9 3 I ~
Example 7 2- [ 9 ( Z ) -Retinoyloxy ]--3 ', 4 ' -dimethoxyacetophenone A mixture of 50 ml of dimethylformamide, 0.75 g of potassium carbonate, 2 . 2 g of 2-chloro-3 ', 4 ' -dimethoxyacetophenone and 3 g of 9 ( Z ) -retinoic acid was stirred under nitrogen at RT with excluslon of light for 24 h. For workup, 100 ml of water were added to the reaction mixture, which was then stirred at RT for 10 2 h. The precipitated crystals were filtered off with suction, recrystallized from isopropanol and dried under nitrogen. This resulted in 3.6 g (969~ of theory) of crystallized product of melting point 130-C.
Example 8 N- [ 1--( D-Glucopyranosyluronosyl ) ] -9 ( Z ) -retinoamide A mixture of 10 g of 9(Z)-retinoic acid and 2.9 g of pyridine in 20 500 ml of diethyl ether was cooled to 0 C under N2 with exclusion of light. Then, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the mixture was stirred at 0 C for 2 h. Precipitated pyridinium hydrochlorida was removed. The filtrate was then cooled to --25 C and a solution of 10 g of methyl (2,3,4-tri-o-acetyl-f~--D--glucopyranosyluronosyl)amine in 150 ml of diethyl ether and 4 . 2 g of potassium carbonate were added. The mixture was stirred at -25 C fo 2 h and warmed to 0 C over the course of 1 h. Then 2 g of potassium carbonate and 100 ml of methanol were added to the reaction mixture. To remove the protective groups, a 30 20~ strength solution of ROE~ in 150 ml of methanol was then added. The reaction mixture was heated at 60 C for 0.5 h and then cooled to RT. After extraction with heptane/ethyl acetatQ, the aqueous phases were extracted several times with methylene chloride. The methylene chloride phases were then concentrated under reduced pressure. The residue was fractionated into a 1:1 mixture of the two anomers by chromatography on silica gel. This 1:1 mixture of isomers of the abovementioned product was obtained in amounts of 8.2 g (corre~ponding to 609~ of theory) with a solidification point of 56-58 C.
Example 9 Tocopheryl 9 ( Z ) -retinoate 6 g of 9(Z)-retinoic acid were dissolved in 150 ml of diisopropyl ether, and the solution was cooled to 5 C. Then 4 . 6 g of tri-f luoroacetic anhydride were added dropwise, and the reaction lo 2~9~1d mixture waa warmed to RT . A solut1on of 9 . 6 g of D, L-tocopherol in 10 ml of diisopropyl ether was then added dropwise, and the mixture was stirred at RT for 1 h. For workup, 20 ml of agueous ammonia were added to the mixture at 20 - 25 C. After phase Eieparation, the organic phase was wa3hed with water, dried and then distllled to remove the solvent. 12 g (corresponding to 84 of theory) of the abovementioned product were obtained in the form of an orange-yellow oil whose NMR data agree with the proposed structure.
Example 1 0 Ergocalciferyl 9 ( Z )-retinoate A mixture of 10 g of 9(Z)-retinoic acid, 2.9 g of pyridine and 500 ml of diethyl ether was cooled under N2 protective gas with exclusion of light to 0 C and, at 0 C, 3.5 g of thionyl chloride were added dropwise, and the reaction mixture was stirred at 0 C
for 2 h. Precipitated pyridinium hydrochloride wa~ removed. The 20 filtrate was cooled to -2S C and a solution o~ 13.2 g of ergo-calciferol in lS0 ml of diethyl ether and 4.2 g of potassium carbonate were added. The mixture was stirred at -25 C for 2 h and then warmed to 0 C over the course of 1 h. 'rhen lO~t strength aqueous KHC03 solution was added to the reaction mixture, followed by wash$ng with water. Removal of the solvent by distillation resulted in lS g of the abovementioned product in the form of a dark orange oil. The NMR spectra are consistent with the propo3ed ~ tructure .
Claims (5)
1. Esters and amides of 9(Z)-retinoic acid for use for treating carcinomas, of the formula I
(I), where Y can be the following radicals:
, where R1 is H or C1-C20-alkyl or C1-C20-alkanoyl and R2 is C1-C4-alkyl, -CH2OH, -NR?, -CH2-O-CO-R3, , , , , or and where R3 is H or C1-C4-alkyl, X is H, F, Cl, Br, I, -OH, -OR3, -NH2, -NO2, -CN, -NHR3, -NR?, -SH, SR3, -O-CO-R3, -CO-R3, -CHO or -CO-OR3, and n is an integer from 0 to 5, or else Y is ; ;
; ;
; ;
;
; , ; ; , where R1, R3, X and n have the abovementioned meanings, and R4 is -CO-OR3, -CO-R3 or , where in the compounds which contain several R1, R2, R3 and/or R4 radicals, these can be identical or different, or else Y is one of the radicals where R3 has the abovementioned meaning, and R5 is H or C1-C4-alkyl or C1-C4-alkanoyl.
(I), where Y can be the following radicals:
, where R1 is H or C1-C20-alkyl or C1-C20-alkanoyl and R2 is C1-C4-alkyl, -CH2OH, -NR?, -CH2-O-CO-R3, , , , , or and where R3 is H or C1-C4-alkyl, X is H, F, Cl, Br, I, -OH, -OR3, -NH2, -NO2, -CN, -NHR3, -NR?, -SH, SR3, -O-CO-R3, -CO-R3, -CHO or -CO-OR3, and n is an integer from 0 to 5, or else Y is ; ;
; ;
; ;
;
; , ; ; , where R1, R3, X and n have the abovementioned meanings, and R4 is -CO-OR3, -CO-R3 or , where in the compounds which contain several R1, R2, R3 and/or R4 radicals, these can be identical or different, or else Y is one of the radicals where R3 has the abovementioned meaning, and R5 is H or C1-C4-alkyl or C1-C4-alkanoyl.
2 . Esters and amides of 9 (Z) -retinoic acid for use for treating carcinomas, of the formula I as claimed in claim 1, where Y
9 the radical where R1 is H, X is F, -OH, -OCH3, -NH2, -CN, -NHCH3 or -N(CH3)2, and n is an integer from 1 to 3.
9 the radical where R1 is H, X is F, -OH, -OCH3, -NH2, -CN, -NHCH3 or -N(CH3)2, and n is an integer from 1 to 3.
3. Amides of 9 (Z) -retinoic acid for use for treating carcinomas, of the formula I as claimed in claim 1, where Y is one of the radicals where R5 is H, C1-C4-alkyl or C1-C4-alkanoyl and R3 is H, C1-C4-alkanoyl or C1-C4-alkyl,
4. Esters or amides of 9(Z)-retinoic acid of the formula I
, (I), where Y is ; ;
; ;
; ;
;
;
;
.
;
, (I), where Y is ; ;
; ;
; ;
;
;
;
.
;
5. A pharmaceutical composition containing esters and amides of 9 (Z) -retinoic acid as claimed in claims 1 to 4 in addition to conventional pharmaceutical excipients or diluents and con-ventional pharmaceutical ancillary substances.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19523079.5 | 1995-06-26 | ||
DE19523079A DE19523079A1 (en) | 1995-06-26 | 1995-06-26 | Esters and amides of 9 (Z) -retinoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2179314A1 true CA2179314A1 (en) | 1996-12-27 |
Family
ID=7765222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002179314A Abandoned CA2179314A1 (en) | 1995-06-26 | 1996-06-17 | Esters and amides of 9(z)-retinoic acid |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0751125A1 (en) |
JP (1) | JPH0912538A (en) |
CA (1) | CA2179314A1 (en) |
DE (1) | DE19523079A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1068181B1 (en) * | 1998-03-30 | 2003-05-07 | Lg Chemical Limited | Polyethoxylated retinamide derivatives and process for preparing the same |
US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
RU2232758C2 (en) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Tocopherols, tocotrienols and other derivatives of chroman and by-side chains and methods for treatment with their using |
CA2399802C (en) | 2000-02-11 | 2009-12-08 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
DE10255861A1 (en) * | 2002-11-29 | 2004-06-17 | Axxima Pharmaceuticals Ag | Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase |
AU2004206900B2 (en) * | 2003-01-17 | 2011-03-10 | Wisconsin Alumni Research Foundation | Modified retinoid compounds and their uses |
CA2513586A1 (en) * | 2003-01-17 | 2004-08-05 | Wisconsin Alumni Research Foundation | Method of reducing toxicity of retinoids |
BRPI0513145A (en) * | 2004-07-09 | 2008-04-29 | Dsm Ip Assets Bv | amino, amino acid or retinoic acid peptide conjugates |
PL2125697T3 (en) * | 2007-01-15 | 2017-01-31 | Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
EP2420228A1 (en) | 2010-08-05 | 2012-02-22 | Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG | Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer |
KR101875394B1 (en) * | 2015-12-07 | 2018-07-06 | 엔프라니 주식회사 | Retinoid Compounds containing dopamine and preparing method thereof |
WO2018217873A1 (en) * | 2017-05-23 | 2018-11-29 | The Regents Of The University Of Michigan | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof |
JP2019006795A (en) * | 2018-08-27 | 2019-01-17 | チョンシー ユー | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2300107C2 (en) * | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A acid anilide-4-carboxylic acid ethyl ester, process for its production and preparations containing it |
US4677120A (en) * | 1985-07-31 | 1987-06-30 | Molecular Design International | Topical prodrugs for treatment of acne and skin diseases |
JPH04244076A (en) * | 1991-01-30 | 1992-09-01 | Nisshin Flour Milling Co Ltd | Vitamin a acid ester compound |
JP2835195B2 (en) * | 1991-01-30 | 1998-12-14 | 日清製粉株式会社 | Vitamin A acid ester compound |
CZ282548B6 (en) * | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Application of 9-cis-retinic acid |
-
1995
- 1995-06-26 DE DE19523079A patent/DE19523079A1/en not_active Withdrawn
-
1996
- 1996-06-17 CA CA002179314A patent/CA2179314A1/en not_active Abandoned
- 1996-06-17 EP EP96109672A patent/EP0751125A1/en not_active Withdrawn
- 1996-06-20 JP JP8159890A patent/JPH0912538A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
DE19523079A1 (en) | 1997-01-02 |
JPH0912538A (en) | 1997-01-14 |
EP0751125A1 (en) | 1997-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4405602B2 (en) | Histone deacetylase inhibitor | |
JP3121343B2 (en) | Novel ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds | |
CA2179314A1 (en) | Esters and amides of 9(z)-retinoic acid | |
EP0291159A2 (en) | Aminosalicylic-acid derivatives for the treatment of psoriasis | |
JPS61197554A (en) | Novel anilide | |
US10087149B2 (en) | Selective histone deacetylase 8 inhibitors | |
EP3252039B1 (en) | Compound containing indoleacetic acid core structure and use thereof | |
AU2018209577B2 (en) | Linked cyclic compound as caspase inhibitor | |
FI118766B (en) | New diosmethine compounds, process for their preparation and pharmaceutical compositions containing these compounds | |
CA2116617C (en) | Novel esculetin derivatives and pharmaceutical composition | |
PL150841B1 (en) | Purine compounds. | |
JPS609716B2 (en) | 1,2-Benzinthiazolin-3-ones, their production method and use as medicine | |
EP0293899B1 (en) | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | |
AU657825B2 (en) | Substituted benzaldehyde derivatives | |
EP3397627B1 (en) | Indolizine derivatives, composition and methods of use | |
US4897423A (en) | Dinitrobenzenesulfonamides | |
IE61437B1 (en) | Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative | |
CN109836477B (en) | Phenylalanine derivative containing benzothiadiazine-3-ketone 1, 1-dioxide and preparation method and application thereof | |
CA2143000C (en) | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors | |
KR100876371B1 (en) | L-ascorbic acid-2-O-maleic acid-alpha-tocopherol diester 1-propanol adduct and its manufacturing method | |
EP4357346A1 (en) | External anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | |
EP2647622B1 (en) | Kinesin spindle protein inhibitors and application thereof | |
US7074938B2 (en) | Method for the synthesis of soritin compounds | |
SK87096A3 (en) | Pharmaceutical composition | |
JP3331046B2 (en) | Brain lipid peroxidation inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |